• 1
    Jemal A, Bray F, Center M, Ferlay J, Ward E, Forman D. Cancer statistics, 2010. CA Cancer J Clin 2011; 61: 6990.
  • 2
    Ferlay J, Parkin DM, Steliarova-Faucher E. Estimates of the cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46: 765781.
  • 3
    Heidenreich A, Aus G, Bolla M, Joniau S et al. European Association of Urology Guidelines on Prostate Cancer. Eur Urol 2008; 53: 6880.
  • 4
    Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998; 280: 975980.
  • 5
    Chodak GW, Thisted RA, Gerber GS, Johansson JE et al. Results of conservative management of clinically localized prostate cancer. N Engl J Med 1994; 330: 242248.
  • 6
    NICE. National Institute for Health and Clinical Excellence Guidelines: prostate cancer: diagnosis and treatment. London, UK: National Collaborating Centre for Cancer, 2008.
  • 7
    Crawford ED, Petrylak D. Castration-resistant prostate cancer: descriptive yet pejorative? J Clin Oncol 2010; 28: e408.
  • 8
    Guidelines on prostate cancer: European Association of Urology, 2009. Available from: (Accessed 31 March 2010).
  • 9
    Alemayehu B, Buysman E, Parry D, Becker L, Nathan F. Economic burden and healthcare utilization associated with castration-resistant prostate cancer in a commercial and Medicare Advantage US patient population. J Med Econ 2010; 13: 351361.
  • 10
    Berruti A, Mosca A, Porpiglia F, Bollito E et al. Chromogranin A expression in patients with hormone naive prostate cancer predicts the development of hormone refractory disease. J Urol 2007; 178: 838843 [quiz 1129].
  • 11
    Morgan C, McEwan P, Chamberlain G, Cabrera C, Parry D. Castration-resistant prostate cancer (CRPC): a UK epidemiology study. Value Health 2010; 13: A26 [abstract PCN17].
  • 12
    Bianco FJ Jr, Wood DP Jr, Cher ML, Powell IJ et al. Ten-year survival after radical prostatectomy: specimen Gleason score is the predictor in organ-confined prostate cancer. Clin Prostate Cancer 2003; 1: 242247.
  • 13
    Inoue T, Segawa T, Kamba T, Yoshimura K et al. Prevalence of skeletal complications and their impact on survival of hormone refractory prostate cancer patients in Japan. Urology 2009; 73: 11041109.
  • 14
    Berruti A, Tucci M, Mosca A, Tarabuzzi R et al. Predictive factors for skeletal complications in hormone-refractory prostate cancer patients with metastatic bone disease. Br J Cancer 2005; 93: 633638.
  • 15
    Soerdjbalie-Maikoe V, Pelger RC, Lycklama a Nijeholt GA, Arndt JW et al. Bone scintigraphy predicts the risk of spinal cord compression in hormone-refractory prostate cancer. Eur J Nucl Med Mol Imaging 2004; 31: 958963.
  • 16
    Chin SN, Wang L, Moore M, Sridhar SS. A review of the patterns of docetaxel use for hormone-resistant prostate cancer at the Princess Margaret Hospital. Curr Oncol 2010; 17: 2429.
  • 17
    Smith MR, Kabbinavar F, Saad F, Hussain A et al. Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol 2005; 23: 29182925.
  • 18
    Hwang SS, Chang VT, Alejandro Y, Mulaparthi S et al. Study of hormone refractory prostate cancer: hospital care and palliative care resource use at a VA medical center. Cancer Invest 2004; 22: 849857.
  • 19
    Sullivan PW, Mulani PM, Fishman M, Sleep D. Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer. Qual Life Res 2007; 16: 571575.
  • 20
    Cabrera C, Hirst C, Hayflinger C, Koo L. Co-morbidity among hormone resistant prostate cancer patients in the US. Pharmacoepidemiol Drug Safety 2010; 19(A615):S1S347.
  • 21
    Antonarakis ES, Eisenberger MA. Expanding treatment options for metastatic prostate cancer. N Eng J Med 2011; 364: 20552058.
  • 22
    Halabi S, Vogelzang NJ, Ou SS, Small EJ. The impact of prior radical prostatectomy in men with metastatic castration recurrent prostate cancer: a pooled analysis of 9 Cancer and Leukemia Group B Trials. J Urol 2007; 177: 531534.
  • 23
    Abouassaly R, Paciorek A, Ryan CJ, Carroll PR, Klein EA. Predictors of clinical metastasis in prostate cancer patients receiving androgen deprivation therapy: results from CaPSURE. Cancer 2009; 115: 44704476.
  • 24
    Norgaard M, Jensen AO, Jacobsen JB, Cetin K et al. Skeletal related events, bone metastasis and survival of prostate cancer: a population based cohort study in Denmark (1999 to 2007). J Urol 2010; 184: 162167.
  • 25
    Altekruse SF, Kosary CL, Krapcho M, Neyman N et al. SEER cancer statistics review, 1975–2007, Bethesda, MD: National Cancer Institute,, based on November 2009 SEER data submission, posted to the SEER web site, 2010. 2010.
  • 26
    Kato I, Severson RK, Schwartz AG. Conditional median survival of patients with advanced carcinoma: surveillance, epidemiology, and end results data. Cancer 2001; 92: 22112219.
  • 27
    Daniell HW, Dunn SR, Ferguson DW, Lomas G et al. Progressive osteoporosis during androgen deprivation therapy for prostate cancer. J Urol 2000; 163: 181186.
  • 28
    Daniell HW. Osteoporosis after orchiectomy for prostate cancer. J Urol 1997; 157: 439444.
  • 29
    Baker J, Ajani J, Scotte F, Winther D et al. Docetaxel-related side effects and their management. Eur J Oncol Nurs 2009; 13: 4959.